Machine learning selects CSF and serum protein panels associated with early Alzheimer disease
In a proteomic study, researchers measured paired CSF and serum samples in a discovery cohort and used random-forest machine learning to select a 19-protein CSF panel and an eight-protein serum panel to distinguish mild cognitive impairment due to Alzheimer disease from cognitively normal participants. Targeted proteomics verified candidate proteins in an independent multicenter cohort. In small held-out test groups, the CSF panel reached AUC 0.984 and the serum panel AUC 0.881; the CSF panel also distinguished Alzheimer-related MCI from frontotemporal dementia, ALS and Huntington disease in the reported analyses.
Technology: Random-forest machine-learning classifiers on CSF and serum proteomic profiles
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: In a proteomic study, researchers measured paired CSF and serum samples in a discovery cohort and used random-forest machine learning to select a 19-protein CSF panel and an eight-protein serum panel to distinguish mild cognitive impairment due to Alzheimer disease from cognitively normal participants.
- Still unknown: The AUC test sets were small (CSF: 9 Alzheimer-related MCI and 21 controls; serum: 8 and 21). The study used separate independent multicenter targeted-proteomics validation for candidate proteins; that does not make the small classifier test cohorts large or establish clinical utility. The serum panel was less effective at distinguishing Alzheimer-related MCI from other neurodegenerative diseases than the CSF panel. These are research panels, not routine tests.
- AI role: Random forests prioritized 19 CSF proteins and eight serum proteins to form disease-specific MCI classifiers after proteomic discovery and targeted validation; the selected panels were evaluated in held-out samples and against other neurodegenerative diseases.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC10794110/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 66 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.